TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line RecurrenVMetastatic Head and Neck Squamous Cell Carcinoma (RIM HNSCC)
Key publications on targeted therapy in head and neck cancers
Chairpersons :
R. Gopal, S. H. Advani
Reviewer :
Avinash Pandey